Cell Lab Med

About Cell Lab Med

CellabMED is a pioneering biotechnology company focused on developing innovative cell and gene therapies to treat rare and refractory cancers. The company operates in the highly specialized field of oncology, aiming to address high medical unmet needs with effective and safe therapeutic solutions. CellabMED's core products include CAR T cell therapies and therapeutic antibodies, which are designed to offer new hope to cancer patients by targeting specific molecular and genomic traits of tumors. The company serves a diverse range of clients, including healthcare providers, research institutions, and pharmaceutical companies, primarily in the oncology market.

CellabMED's business model revolves around a fully integrated R&D system that spans from basic research to clinical development and manufacturing. This comprehensive approach allows the company to maintain control over the entire development pipeline, ensuring high-quality and effective treatments. Revenue is generated through a combination of product sales, licensing agreements, and partnerships with other biotech and pharmaceutical companies.

Key milestones include the preclinical development of a humanized neutralizing antibody targeting HGF in 2017, the identification of therapeutic vulnerabilities in glioblastoma in 2019, and the initiation of a first-in-human phase I trial for an anti-HGF antibody in 2020. These achievements highlight CellabMED's commitment to advancing cancer treatment through cutting-edge science and innovation.